DOCSLIB.ORG

Moderna COVID-19 Vaccine: Standing Orders for Administering

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Moderna COVID-19 Vaccine Statewide Standing Order for Administering Vaccine to Persons 18 Years of Age and Older Note: For more information/guidance, please contact the Washington State Department of Health or your local health jurisdiction. » Purpose For people who received a COVID-19 vaccine that is not currently authorized in the United States, guidance can be found at: https://www.cdc.gov/ To reduce morbidity and mortality from coronavirus disease 2019 vaccines/covid-19/info-by-product/clinical-considerations.html#not- (COVID-19) by vaccinating persons who meet the criteria established by authorized-vaccines the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP). Moderna COVID-19 vaccine may be coadministered with other vaccines on » Policy the same day, as well as within 14 days of each other. ¶ Defer vaccination with Moderna COVID-19 Vaccine for at least 90 days for This standing order enables health care professionals authorized by persons who received passive antibody therapy law to administer COVID-19 vaccines in the State of Washington to (monoclonal antibodies or convalescent plasma) as part of assess and vaccinate persons who meet the criteria in the"Procedure" COVID-19 treatment. section below without the need for clinician examination or direct order from the attending provider at the time of the interaction. Do not administer if any contraindication or precaution is identified through screening. » Procedure Contraindications: . Assess persons 18 years of age and older for vaccination with Moderna ○ COVID-19 Vaccine based on the following criteria: » Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of an mRNA COVID-19 vaccine ○ History of myocarditis or pericarditis after receiving the first dose of an (Moderna or Pfizer-BioNTech) mRNA COVID-19 vaccine • Defer the second dose of an mRNA COVID-19 vaccine. » Immediate allergic reaction± of any severity to a previous dose or known Administration of the second dose of an mRNA COVID-19 vaccine (diagnosed) allergy to a component of the vaccine (see Table 1 in this document for a list of vaccine components) series can be considered in certain circumstances after the episode of myocarditis or pericarditis has completely resolved. ○ Precautions: Considerations can be found at https://www.cdc.gov/vaccines/ covid-19/clinical-considerations/covid-19-vaccines- » History of an immediate allergic reaction± of any severity to any other vaccine or injectable therapy (i.e., intramuscular, intravenous, or us.html#underlying-conditions subcutaneous vaccines or therapies) ○ History of myocarditis or pericarditis prior to COVID-19 vaccination • This includes persons with a reaction to a vaccine or injectable therapy • May receive any FDA-authorized COVID-19 vaccine after that contains multiple components, one of which is polyethylene glycol the episode of myocarditis or pericarditis has completely resolved (PEG) or another vaccine component, but for whom it is unknown which component elicited the immediate allergic reaction. ○ Has not completed a COVID-19 vaccination series, regardless of brand. If 2 doses of an mRNA vaccine have been administered or a single dose of • People with a contraindication to Janssen COVID-19 Vaccine have a Janssen vaccine has been administered, no additional doses are precaution to both mRNA vaccines (see footnote)# recommended unless the person is eligible for a third dose as described below. » Moderate to severe acute illness ○ If the recipient has received 1 previous dose of Moderna COVID-19 Vaccine, administer the second dose at an interval of least 28 days *Administer the second dose as close as possible to the recommended interval (28 days). If the second dose is not administered within 42 days of the first dose, the series does not need to be restarted. Doses inadvertently administered less than 28 days apart (but preferably before 42 days).* do not need to be repeated. ¶When deciding whether tocoadminister COVID-19 vaccineand other vaccines, providers should consider whether the patient is behind or ○ If the vaccine product given as the first dose cannot be determined or is no at risk of becoming behind on recommended vaccines., They should also consider the patient’s risk of vaccine-preventable diseases (e.g., during an outbreak) and the reactogenicity profile of the vaccines. longer available, any mRNA COVID-19 vaccine product may be administered at ±An immediate allergic reaction is defined as any hypersensitivity-related signs or symptoms such as urticaria, angioedema, least 28 days after the first dose. respiratory distress (e.g., wheezing, stridor), or anaphylaxis that occur within 4 hours following exposure to a vaccine or medication. #Consider consultation with an allergist-immunologist to help determine if a patient with a contraindication to an mRNA vaccine can safely receive the Janssen COVID-19 vaccine. Healthcare providers and health ○ If the recipient has completed a Moderna COVID-19 vaccination series, an departments may also request a consultation from the Clinical Immunization Safety Assessment COVIDvax project. Vaccination of additional Moderna COVID-19 vaccine dose may be given at least 28 days after these individuals should only be done in an appropriate setting under the supervision of a healthcare provider experienced in the an initial 2-dose Moderna COVID-19 vaccine series for immunocompromised management of severe allergic reactions. People with a contraindication to mRNA COVID-19 vaccines (including due to a known PEG allergy) have a precaution to people who self-attest or confirm they are moderately or severely Janssen COVID-19 vaccination. People who have previously received an mRNA COVID-19 vaccine dose should wait at least immunocompromised due to any of the following: active or recent treatment 28 days to receive Janssen COVID-19 Vaccine. People with a contraindication to Janssen COVID-19 Vaccine (including due to a known polysorbate allergy) have a for solid tumor and hematologic malignancies, receipt of solid-organ or recent precaution to mRNA COVID-19 vaccination. hematopoietic stem cell transplant, severe primary immunodeficiency, advanced § Educational materials are available at www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html or untreated HIV infection, or any other conditions as defined by the Advisory †Educational materials are available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/JJUpdate.html Committee on Immunization Practices recommendations available in the Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States as eligible for third dose. If the Moderna COVID-19 vaccine is not available, a Pfizer-BioNTech COVID-19 vaccine may be administered as a replacement. A person should not receive more than three mRNA COVID-19 vaccine doses. Inform recipients, especially males 12 through 29 years of age and their parents/ legal representative (when relevant) of the possibility of myocarditis or pericarditis following receipt of mRNA COVID-19 vaccines and the need to seek care if symptoms of myocarditis or pericarditis develop after vaccination.§ 08/19/2021 1 Moderna COVID-19 Vaccine Statewide Standing Order for Administering Vaccine to Persons 18 Years of Age and Older Sex and Weight of Patient Needle Gauge Needle Length Injection Site† Female or male fewer than 130 lbs 22–25 5/8 § –1" Deltoid muscle of arm Female or male 130–152 lbs 22–25 1" Deltoid muscle of arm Female 152–200 lbs 22–25 1–11/2" Deltoid muscle of arm Male 152–260 lbs 22–25 1–11/2" Deltoid muscle of arm Female 200+ lbs 22–25 11/2" Deltoid muscle of arm Male 260+ lbs 22–25 11/2" Deltoid muscle of arm †Alternately, the anterolateral thigh can be used. A 1.5-inch needle may be used if administering vaccine in this site. §Some experts recommend a 5/8-inch needle for men and women who weigh less 130 pounds. If used, skin must be stretched tightly (do not bunch subcutaneous tissue). Provide all recipients with a copy of the current federal Be prepared to manage medical emergencies. Emergency Use Authorization (EUA) Fact Sheet for ○ Vaccination providers should observe patients after Recipients and Caregivers. vaccination to monitor for the occurrence of immediate Prepare to administer the vaccine. Choose the correct needle adverse reactions, including syncope: gauge, needle length, and injection site for persons: » 30 minutes: Persons with a: ○ 18 years of age: History of an immediate allergic reaction of any severity » Needle gauge/length: 22-25 gauge, 1-inch. to a vaccine or injectable therapy » Site: Deltoid muscle of arm. Contraindication to Janssen COVID-19 Vaccine who receive Moderna COVID-19 Vaccine ○ 19 years of age and older: See chart above. Follow the manufacturer's guidance for storing/handling History of anaphylaxis due to any cause punctured vaccine vials. » 15 minutes: All other persons Administer 0.5 mL Moderna COVID-19 Vaccine by ○ Syncope may occur in association with injectable vaccines, in intramuscular (IM) injection. particular among adolescents. Procedures should be in place Document vaccination. to avoid falling injuries and manage syncopal reactions. ○ COVID-19 vaccination providers must document vaccine ○ Have a written protocol to manage medical emergencies administration in their medical record systems within following vaccination, as well as equipment and 24 hours of administration and use their best efforts to medications, including at least
Recommended publications
  • Uniqure N.V. Paasheuvelweg 25A 1105BP Amsterdam the Netherlands +1-339-970-7000

    Uniqure N.V. Paasheuvelweg 25A 1105BP Amsterdam the Netherlands +1-339-970-7000

    uniQure N.V. Paasheuvelweg 25a 1105BP Amsterdam The Netherlands +1-339-970-7000 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on September 14, 2017 To the Shareholders of uniQure N.V.: Notice is hereby given that an Extraordinary General Meeting of Shareholders (the “Extraordinary Meeting”) of uniQure N.V., a public company with limited liability ( naamloze vennootschap ) under the laws of the Netherlands (the “Company,” “uniQure,” and “we”), will be held on September 14, 2017, at 9:30 a.m., Central European Summer Time, at the Company’s principal executive offices located at Paasheuvelweg 25a, 1105BP Amsterdam, the Netherlands, for the following purposes: I. Opening and announcements; II. Appointment of Jeremy P. Springhorn, Ph.D. as a non-executive director (voting proposal no. 1); III. Appointment of Madhavan Balachandran as a non-executive director (voting proposal no. 2); IV Any other business that may properly come before the meeting or any adjournment of the meeting; and V. Closing of the meeting. Each person authorized to attend the Extraordinary Meeting may inspect the Agenda at the office of uniQure. Our Board of Directors (our “Board”) recommends that you vote “FOR” each of the voting proposals noted above. The record date is set at the close of business on August 17, 2017 EST and, therefore, only the Company’s shareholders of record at the close of business on August 17, 2017 EST are entitled to receive this notice (this “Notice”) and to vote at the Extraordinary Meeting and any adjournment thereof. Only shareholders who have given notice in writing to the Company by September 12, 2017 of their intention to attend the Extraordinary Meeting in person are entitled to attend the Extraordinary Meeting in person.
  • COVID-19 Vaccines: Update on Allergic Reactions, Contraindications, and Precautions

    COVID-19 Vaccines: Update on Allergic Reactions, Contraindications, and Precautions

    Centers for Disease Control and Prevention Center for Preparedness and Response COVID-19 Vaccines: Update on Allergic Reactions, Contraindications, and Precautions Clinician Outreach and Communication Activity (COCA) Webinar Wednesday, December 30, 2020 Continuing Education Continuing education will not be offered for this COCA Call. To Ask a Question ▪ All participants joining us today are in listen-only mode. ▪ Using the Webinar System – Click the “Q&A” button. – Type your question in the “Q&A” box. – Submit your question. ▪ The video recording of this COCA Call will be posted at https://emergency.cdc.gov/coca/calls/2020/callinfo_123020.asp and available to view on-demand a few hours after the call ends. ▪ If you are a patient, please refer your questions to your healthcare provider. ▪ For media questions, please contact CDC Media Relations at 404-639-3286, or send an email to [email protected]. Centers for Disease Control and Prevention Center for Preparedness and Response Today’s First Presenter Tom Shimabukuro, MD, MPH, MBA CAPT, U.S. Public Health Service Vaccine Safety Team Lead COVID-19 Response Centers for Disease Control and Prevention Centers for Disease Control and Prevention Center for Preparedness and Response Today’s Second Presenter Sarah Mbaeyi, MD, MPH CDR, U.S. Public Health Service Clinical Guidelines Team COVID-19 Response Centers for Disease Control and Prevention National Center for Immunization & Respiratory Diseases Anaphylaxis following mRNA COVID-19 vaccination Tom Shimabukuro, MD, MPH, MBA CDC COVID-19 Vaccine
  • Third Quarter 2020

    Third Quarter 2020

    March 31, 2020 Third Quarter 2020 Corporate update and financial results November 10, 2020 Forward-looking statements Various statements in this slide presentation concerning the future expectations of BioNTech, its plans and prospects, including the Company's views with respect to the potential for mRNA and other pipeline therapeutics; BioNTech's efforts to combat COVID-19; the collaborations between BioNTech and Pfizer and Fosun to develop a potential COVID-19 vaccine; our expectations regarding the potential characteristics of BNT162b2 in our continuing Phase 2/3 trial and/or in commercial use based on data observations to date; the expected timepoint for additional readouts on efficacy data of BNT162b2 in our Phase 2/3 trial; the nature of the clinical data for BNT162, BNT311 and our other product candidates, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any potential approval or Emergency Use Authorization with respect to our BNT162 program; the timing for submission of BNT162 manufacturing data to the FDA; the ability of BioNTech to supply the quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimates for 2020 and 2021 and orders received to-date; the planned next steps in BioNTech's pipeline programs and specifically including, but not limited to, statements regarding plans to initiate clinical trials of BioNTech's product candidates and expectations for data announcements with
  • Interim Recommendations for Use of the Moderna Mrna-1273 Vaccine Against COVID-19

    Interim Recommendations for Use of the Moderna Mrna-1273 Vaccine Against COVID-19

    Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19 Interim guidance First issued 25 January 2021 Updated 15 June 2021 Background This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) at its extraordinary meeting on 21 January 2021 (1) and updated during its extraordinary meeting on 27 May 2021(2). Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries of the reported interests can be found on the SAGE meeting website and SAGE Working Group website. The guidance is based on the evidence summarised in the Background document on the Moderna mRNA-1273 vaccine against COVID-19 (3) and the background paper on COVID-19 disease and vaccines (4). Annexes which include GRADE and evidence-to-recommendations (ETR) tables have also been updated to reflect the updated recommendations. All referenced documents are available on the SAGE COVID-19 webpage: https://www.who.int/groups/strategic- advisory-group-of-experts-on-immunization/covid-19-materials. These interim recommendations refer to the mRNA-1273 vaccine, manufactured by Moderna. The vaccine is also known as COVID-19 Vaccine Moderna. In the subsequent text the vaccine will be referred to as mRNA-1273. On 30 April 2021, mRNA-1273 was granted WHO’s Emergency Use Listing (EUL). Methods SAGE applies the principles of evidence-based medicine and has set in place a thorough methodological process for issuing and updating recommendations (5). A detailed description of the methodological processes as they apply to COVID-19 vaccines can be found in the SAGE evidence framework for COVID-19 vaccines (6).
  • Moderna Vaccine Day Presentation

    Moderna Vaccine Day Presentation

    Zika Encoded VLP mRNA(s) RSV CMV + EBV SARS-CoV- RSV-ped 2 Flu hMPV/PIV3 H7N9 Encoded mRNA(s) Ribosome Protein chain(s) First Vaccines Day April 14, 2020 © 2020 M oderna Therapeutics Forward-looking statements and disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended including, but not limited to, statements concerning; the impact of the SARS-CoV-2 pandemic on the Company’s clinical trials and operations; the timing and finalization of a dose-confirmation Phase 2 study and planning for a pivotal Phase 3 study for mRNA-1647; the status and outcome of the Phase 1 clinical trial for mRNA-1273 being conducted by NIH; the next steps and ultimate commercial plan for mRNA-1273; the size of the potential market opportunity for mRNA-1273; the size of the potential commercial market for novel vaccines produced by Moderna or others; the potential peak sales for the Company’s wholly-owned vaccines; the probability of success of the Company’s vaccines individually and as a portfolio; and the ability of the Company to accelerate the research and development timeline for any individual product or the platform as a whole. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements.
  • The Covid–19 Pandemic and Haemoglobin Disorders

    The Covid–19 Pandemic and Haemoglobin Disorders

    THE COVID–19 PANDEMIC AND HAEMOGLOBIN DISORDERS VACCINATIONS & THERAPEUTIC DRUGS An Informational Guide from the Thalassaemia International Federation (TIF) Prepared by: Dr Androulla Eleftheriou, Executive Director, TIF Last Updated: 12 May 2020 VACCINATIONS & THERAPEUTIC DRUGS Introduction It is important to note that there are currently no FDA1 or EMA2-approved or even recommended agents for the treatment of the novel coronavirus (COVID-19), for which the World Health Organization (WHO) declared as pandemic on Wednesday 11th of March 2020. Any agent being used at this time is being administered in an experimental setting under controlled conditions. Thalassaemia International Federation (TIF) has made an effort to compile a list of studies/clinical trials for treatment and vaccines, which is by no means exhaustive as this situation is extremely labile and research in this area is dramatically intensified. New information is anticipated to be added to this guide which is prepared exclusively for TIF’s global thalassemia community. The viral genome was mapped very soon as rom early January 2020 and shared globally. In February 2020, the WHO published an overview of the potential therapeutic candidates for the treatment of COVID-19. The document outlines 76 regimens that have been proposed (as of February 17, 2020) for the treatment of patients infected with the virus. Thirty-eight of these candidates are in the preclinical state with minimal information available on their proposed mechanism, uses, doses routes, or planned trials. Sixteen of the remaining regimens contain an interferon-based product. The rest include a variety of antimicrobials, corticosteroids, convalescent plasma, and biologics. The Director-General of the WHO, Mr Tedros Adhanom, stated on the 10th of April 2020, that more than 70 countries have joined WHO’s trial to accelerate research on effective treatments and 20 Institutions and companies ‘are racing to develop a vaccine’.
  • Investor Presentation

    Investor Presentation

    Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Q1 2021 Results Investor presentation 1 Investor Relations │ Q1 2021 Results Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potential,” “expected,” “will,” “planned,” “pipeline,” “outlook,” or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, potential product launches, or regarding potential future revenues from any such products; or regarding the impact of the COVID-19 pandemic on certain therapeutic areas including dermatology, ophthalmology, our breast cancer portfolio, some newly launched brands and the Sandoz retail and anti-infectives business, and on drug development operations; or regarding potential future, pending or announced transactions; regarding potential future sales or earnings of the Group or any of its divisions; or by discussions of strategy, plans, expectations or intentions; or regarding the Group’s liquidity or cash flow positions and its ability to meet its ongoing financial obligations and operational needs; or regarding our collaboration with Molecular Partners to develop, manufacture and commercialize potential medicines for the prevention and treatment of COVID- 19 and our joining of the industry-wide efforts to meet global demand for COVID-19 vaccines and therapeutics by leveraging our manufacturing capacity and capabilities to support the production of the Pfizer-BioNTech vaccine and to manufacture the mRNA and bulk drug product for the vaccine candidate CVnCoV from CureVac.
  • COVID-19 Mrna Pfizer- Biontech Vaccine Analysis Print

    COVID-19 Mrna Pfizer- Biontech Vaccine Analysis Print

    COVID-19 mRNA Pfizer- BioNTech Vaccine Analysis Print All UK spontaneous reports received between 9/12/20 and 22/09/21 for mRNA Pfizer/BioNTech vaccine. A report of a suspected ADR to the Yellow Card scheme does not necessarily mean that it was caused by the vaccine, only that the reporter has a suspicion it may have. Underlying or previously undiagnosed illness unrelated to vaccination can also be factors in such reports. The relative number and nature of reports should therefore not be used to compare the safety of the different vaccines. All reports are kept under continual review in order to identify possible new risks. Report Run Date: 24-Sep-2021, Page 1 Case Series Drug Analysis Print Name: COVID-19 mRNA Pfizer- BioNTech vaccine analysis print Report Run Date: 24-Sep-2021 Data Lock Date: 22-Sep-2021 18:30:09 MedDRA Version: MedDRA 24.0 Reaction Name Total Fatal Blood disorders Anaemia deficiencies Anaemia folate deficiency 1 0 Anaemia vitamin B12 deficiency 2 0 Deficiency anaemia 1 0 Iron deficiency anaemia 6 0 Anaemias NEC Anaemia 97 0 Anaemia macrocytic 1 0 Anaemia megaloblastic 1 0 Autoimmune anaemia 2 0 Blood loss anaemia 1 0 Microcytic anaemia 1 0 Anaemias haemolytic NEC Coombs negative haemolytic anaemia 1 0 Haemolytic anaemia 6 0 Anaemias haemolytic immune Autoimmune haemolytic anaemia 9 0 Anaemias haemolytic mechanical factor Microangiopathic haemolytic anaemia 1 0 Bleeding tendencies Haemorrhagic diathesis 1 0 Increased tendency to bruise 35 0 Spontaneous haematoma 2 0 Coagulation factor deficiencies Acquired haemophilia
  • Statements Contained in This Release As the Result of New Information Or Future Events Or Developments

    Statements Contained in This Release As the Result of New Information Or Future Events Or Developments

    Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant NEW YORK and MAINZ, GERMANY, July 8, 2021 — As part of Pfizer’s and BioNTech’s continued efforts to stay ahead of the virus causing COVID-19 and circulating mutations, the companies are providing an update on their comprehensive booster strategy. Pfizer and BioNTech have seen encouraging data in the ongoing booster trial of a third dose of the current BNT162b2 vaccine. Initial data from the study demonstrate that a booster dose given 6 months after the second dose has a consistent tolerability profile while eliciting high neutralization titers against the wild type and the Beta variant, which are 5 to 10 times higher than after two primary doses. The companies expect to publish more definitive data soon as well as in a peer-reviewed journal and plan to submit the data to the FDA, EMA and other regulatory authorities in the coming weeks. In addition, data from a recent Nature paper demonstrate that immune sera obtained shortly after dose 2 of the primary two dose series of BNT162b2 have strong neutralization titers against the Delta variant (B.1.617.2 lineage) in laboratory tests. The companies anticipate that a third dose will boost those antibody titers even higher, similar to how the third dose performs for the Beta variant (B.1.351). Pfizer and BioNTech are conducting preclinical and clinical tests to confirm this hypothesis. While Pfizer and BioNTech believe a third dose of BNT162b2 has the potential to preserve the highest levels of protective efficacy against all currently known variants including Delta, the companies are remaining vigilant and are developing an updated version of the Pfizer-BioNTech COVID-19 vaccine that targets the full spike protein of the Delta variant.
  • Biopharma R&D on Treatment and Vaccines

    Biopharma R&D on Treatment and Vaccines

    Biopharma R&D on Treatment and Vaccines Coronavirus: Gilead Readies For Remdesivir Ramp Up, Questions On Profit Motive Demand Could Be High For Antiviral Executive Summary “All of that is at risk in not knowing if the drug If clinical trials prove it effective against COVID-19, works or not – and that is really not with an eye to remdesivir could potentially help millions of commercial,” she added. patients - which raises big questions about funding and access. Mercier said the company was spending more time on considering issues of access to the drug once its safety and efficacy is established – especially in regions of the world with less As vaccines will take around 12 months to developed healthcare systems. develop, companies with antiviral treatments are now been pushed to the front line in the battle Nevertheless, Gilead is contemplating a possible against coronavirus, and Gilead Sciences Inc.’s commercial future for the drug. remdesivir is currently the biggest hope of a drug to treat infected patients. “I have to be honest, commercial opportunity might come if this becomes a seasonal disease The company had big news to talk about on 2 or if stockpiling comes into play, but that is much March at the Cowen Health Care conference, as it later down the line,” concluded Mercier. had announced earlier in the day the acquisition of oncology firm Forty Seven for $4.9bn. (Also see One precedent for a big commercial hit for an “Gilead Calls Forty Seven Buyout Complementary antiviral product is Roche’s Tamiflu (oseltamivir). To Kite, Other IO Efforts” - Scrip, 2 Mar, 2020.) The drug achieved peak revenues of $3bn in 2009, largely down to stockpiling in response to that Speaking at the investor conference, Gilead’s chief year’s H1N1 flu pandemic.
  • Therapeutic Oligos & Peptides

    Therapeutic Oligos & Peptides

    Focus on Therapeutic Oligos & Peptides Enhancing the pharmaceutical properties of peptides To begin the discussion about enhancing or improving pharmaceutical properties, one must fi rst understand “the good, the bad, and the ugly” of peptides (1). The good. Peptides are generally highly potent, selective, and have a low potential for toxicity and low risk of drug-drug interaction. The bad. Peptides are generally not terribly stable in biological matrices, susceptible to protease degradation. The ugly. The polar nature of the peptide bond and the size of peptide molecules makes permeability across cell membranes challenging. In small molecule drug PEGylation development, we commonly think PEGylation refers to the attachment about Lipinski’s rule of fi ve (2), of poly(ethylene glycol) or PEG to which is based on the observation Keyw ds peptides or proteins and is able that most orally administered drugs to improve the pharmacokinetic have common physicochemical PEGylation, lipidation, properties of these molecules. characteristics, namely, glycosylation, PEG increases the hydration shell 1. a molecular mass less than 500 cyclization, of a peptide, making the peptide daltons non-natural amino less susceptible to renal clearance 2. a logP (octanol-water partition acid substitution and protease degradation. coeffi cient) less than 5 PEGylation can also decrease the 3. no more than 5 hydrogen bond immunogenicity potential. There are donors many diff erent PEG molecules that can be covalently 4. no more than 10 (2 x 5) hydrogen bond acceptors. attached to peptides including linear or branched, low Peptides violate each and every one of these rules, molecular weight or high molecular weight.
  • Pfizer-Biontech COVID-19 Vaccine Consent and Screening Form For

    Pfizer-Biontech COVID-19 Vaccine Consent and Screening Form For

    Page 1 of 2 Pfizer-BioNTech COVID-19 Vaccine and COMIRNATY (COVID-19 VACCINE, mRNA) Consent and Screening Form for Individuals Under 18 Years of Age SECTION 1: INFORMATION ABOUT MINOR CHILD TO RECEIVE VACCINE (PLEASE PRINT) MINOR’S NAME (Last) (First) (M.I.) MINOR’S DATE OF BIRTH (MM/DD/YEAR): MINOR’S RACE ETHNICITY Is Minor a person White Black Asian Native American or Alaska Native Hispanic with a disability? Native Hawaiian or Pacific Islander Non-Hispanic YES NO PARENT/LEGAL GUARDIAN’S NAME (First) (M.I.) MINOR’S AGE: MINOR’S (Last) GENDER: M / F ADDRESS PARENT/GUARDIAN DAYTIME PHONE NUMBER AND MOBILE NUMBER: CITY STATE ZIP PARENT/GUARDIAN EMAIL ADDRESS: SECTION 2: SCREENING FOR VACCINE ELIGIBILITY The following questions will help determine if there is any reason your child should not get the COVID-19 vaccine. If you answer “yes” to any question, it does not necessarily mean that your child should not be vaccinated. It just means additional questions may be asked. If a question is not clear, please ask your healthcare provider to explain it. YES NO UNKNOWN 1. Is your child currently feeling sick or ill? 2. Has your child ever received a dose of the COVID-19 vaccine? If yes, which vaccine? Moderna; Pfizer; Janssen (Johnson & Johnson); Comirnaty; another brand of vaccine: _________________ Date: ___________ 3. Has your child ever had an allergic reaction to: (This would include a severe allergic reaction [e.g., anaphylaxis] that required treatment with epinephrine or EpiPen® or that caused you to go to the hospital. It would also include an allergic reaction that caused hives, swelling, or respiratory distress, including wheezing.) A component of a COVID-19 vaccine, including any of the following: o Polyethylene glycol (PEG), which is found in some medications, such as laxatives and preparations for colonoscopy procedures? o Polysorbate, which is found in some vaccines, film coated tablets, and intravenous steroids? A previous dose of COVID-19 vaccine? 4.